Brief: Relay Therapeutics Announces Initial Rly-4008 (Lirafugratinib) Data Demonstrating Durable Responses Across Multiple Fgfr2-Altered Solid Tumors
12/10/2023 21:13
Oct 12 (Reuters) - Relay Therapeutics Inc RLAY.O :
* RELAY THERAPEUTICS ANNOUNCES INITIAL RLY-4008
(LIRAFUGRATINIB)
DATA DEMONSTRATING DURABLE RESPONSES ACROSS MULTIPLE
FGFR2-ALTERED SOLID TUMORS
* RELAY THERAPEUTICS INC- PIPELINE UPDATES EXTEND CASH
RUNWAY BY 1
YEAR INTO 2H2026
* RELAY THERAPEUTICS INC- CLINICAL FOCUS ON PI3KΑ MUTANT
SELECTIVE
PROGRAMS, WITH PLANS TO INITIATE RLY-2608 TRIPLET COMBINATIONS
IN HR+/HER2- BREAST CANCER BY YE 2023
* RELAY THERAPEUTICS INC- RLY-4008 COMMERCIALIZATION PLANS
TO
FOCUS ON BROADER TUMOR AGNOSTIC OPPORTUNITIES
Source text for Eikon: ID:nGNX5jMbtm
Further company coverage: RLAY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relay Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Moderna, Kontoor Brands, Ralph Lauren
U.S. STOCKS ON THE MOVE- Intuit, Deere, Advance Auto Parts
U.S. STOCKS ON THE MOVE-Keysight Technologies, Relay Therapeutics, Ralph Lauren
Relay Therapeutics gains after $275 mln equity raise
Brief: Relay Therapeutics Announces Pricing Of Public Offering Of Common Stock